For­ward Ther­a­peu­tics, the first biotech from Curie.Bio, rais­es $50M for oral small mol­e­cules in im­munol­o­gy

An 18-month-old Flori­da biotech has raised a $50 mil­lion Se­ries A to wade in­to the hot im­munol­o­gy and in­flam­ma­tion (I&I) field with oral small mol­e­cules.

For­ward Ther­a­peu­tics un­veiled the fi­nanc­ing from BVF Part­ners, RA Cap­i­tal Man­age­ment and Or­biMed on Wednes­day morn­ing. The start­up will use the funds to gath­er Phase I da­ta with­in three years for its lead drug can­di­date, CEO Toufike Ka­nouni told End­points News.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER